As of Oct 21
| -0.21 / -2.31%|
The 5 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 11.00. The median estimate represents a +34.98% increase from the last price of 8.89.
The current consensus among 6 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.